Literature DB >> 2156026

Indium-111-antimyosin antibody imaging for detecting different stages of myocardial infarction: comparison with technetium-99m-pyrophosphate imaging.

N Tamaki1, T Yamada, A Matsumori, A Yoshida, T Fujita, H Ohtani, Y Watanabe, Y Yonekura, K Endo, J Konishi.   

Abstract

The diagnostic value of 111In-antimyosin (AM) imaging for identifying myocardial infarction was evaluated in comparison with 99mTc-pyrophosphate (PPi) imaging. Twenty-four patients with various stages of myocardial infarction, ranging from three days to nine months after the onset of infarction, underwent both AM and PPi scans. Of 26 infarct lesions AM scan identified 22 (85%), while PPi scans detected 10 (38%) (p less than 0.01). When less than a week had passed since the onset both scans demonstrated all infarct lesions. For seven subacute lesions studied within one to two weeks of onset, AM scans detected (100%), while PPi scans identified only 2 (29%). Furthermore, AM scans showed discrete myocardial uptake in 7 (64%) of those studied more than two weeks after onset. The intensity of AM uptake in the infarcts studied more than seven days after onset was less than that in acute infarcts studied within seven days of onset (p less than 0.05). These preliminary data indicate that the abnormal myocardial uptake of AM persists beyond the first two weeks when PPi no longer accumulates. Thus, AM scans can be considered to provide a sensitive diagnosis of subacute as well as acute myocardial necrosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156026

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Myocardial uptake of antimyosin antibody compared with serum myosin light chain I levels in patients with myocardial infarction.

Authors:  M Suehiro; M Fukuchi; H Naruse; T Iwasaki
Journal:  Ann Nucl Med       Date:  1992-02       Impact factor: 2.668

Review 2.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 3.  Clinical role of indium-111 antimyosin imaging.

Authors:  S Bhattacharya; A Lahiri
Journal:  Eur J Nucl Med       Date:  1991

4.  Indium-111 myosin-specific antibodies and technetium-99m pyrophosphate in the detection of acute cardiac rejection of transplanted hearts: studies in a heterotopic rat heart model.

Authors:  K Takeda; K Ueda; U Scheffel; H Ravert; N D LaFrance; W A Baumgartner; B A Reitz; A Herskowitz; H N Wagner
Journal:  Eur J Nucl Med       Date:  1991

Review 5.  Antibody imaging in the evaluation of cardiovascular diseases.

Authors:  B A Khaw; J Narula
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

Review 6.  Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury.

Authors:  K H Haider; W H Stimson
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

7.  Quantitative 111In antimyosin antibody imaging to predict the age of myocardial infarction.

Authors:  S Bhattacharya; R Senior; X J Liu; D Jain; A Lahiri
Journal:  Int J Card Imaging       Date:  1992

8.  Technetium-99m antimyosin antibody (3-48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction.

Authors:  R Taillefer; L Boucher; R Lambert; J Grégoire; D C Phaneuf; H Sikorsa
Journal:  Eur J Nucl Med       Date:  1995-05

Review 9.  Imaging cell injury and death.

Authors:  Jeffrey Leppo
Journal:  Curr Cardiol Rep       Date:  2003-01       Impact factor: 2.931

Review 10.  Non-invasive in vivo imaging of myocardial apoptosis and necrosis.

Authors:  Albert Flotats; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.